Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing

Milestone expands India’s role in global biologics manufacturing; collaboration with Cipla underscores commitment to quality and reliability BENGALURU, India–(BUSINESS WIRE)–Kemwell Biopharma Pvt Ltd (“Kemwell”), a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced today that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection … [Read more…]

HSS Investigators Address the Impact of Social Determinants of Health and Perception of Discrimination on Health Outcomes in People with Rheumatologic Diseases

CHICAGO–(BUSINESS WIRE)–Investigators from Hospital for Special Surgery (HSS) presented provocative evidence showing how social determinants of health (SDOH) and perceived discrimination influence the care and outcomes of people with rheumatologic diseases, such as lupus, and demonstrated how healthcare providers can screen for SDOH during patient encounters. They made these presentations at ACR Convergence 2025, the … [Read more…]

NRC Health Announces Third Quarter 2025 Results

 Third quarter TRCV* increased 8% year-over-year to $141.7 million Cash flow from operations increased 46% year-over-year to $13.8 million LINCOLN, Neb.–(BUSINESS WIRE)–National Research Corporation, dba NRC Health, (NASDAQ: NRC), a leader in healthcare experience improvement solutions, today announced results for the third quarter 2025. “We delivered our fourth consecutive quarter of recurring contract value growth, … [Read more…]

Ferring Pharmaceuticals Presents Two New Analyses of Pivotal Trial Data for Follitropin Delta (FE 999049) at ASRM 2025

Analyses from the two Phase 3 RITA trials evaluate both the suitability of age-based dosing as well as the tolerability of treatment with follitropin delta in women undergoing controlled ovarian stimulation. Ferring’s long-standing commitment to helping people build families is illustrated through the company’s investment in developing innovative potential treatment options that advance the science … [Read more…]

RestorixHealth Acquires Multi-Place Hyperbaric Specialist CūtisCare, Establishing Premier Partner for Wound Center Management Services

RestorixHealth adds top-tier hospitals, academic medical centers and hospital systems, expanding to nearly 300 partners across 41 states Combined expertise offers more comprehensive management solutions for partners and supports further growth opportunities METAIRIE, La.–(BUSINESS WIRE)–#WhereHealingHappens–RestorixHealth, the nation’s leading wound care solutions company, today announced it has successfully completed a transaction to acquire CūtisCare, a leader … [Read more…]

Corsera Health Files First Phase 1 Clinical Trial Application for its Lead Preventive RNAi Medicine Program for Cardiovascular Disease

Advancing a once-annual preventive RNAi medicine designed to reduce the two key drivers of cardiovascular disease: LDL-C and blood pressure Filed application for COR-1004, a novel siRNA targeting PCSK9 to reduce LDL-C BOSTON–(BUSINESS WIRE)–Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification … [Read more…]

New Poll Reveals Canadians Lack Understanding of Obesity as a Chronic Disease, Stigma Likely Bleeds Into Treatment

– Ahead of generic alternatives to weight loss medication expected to hit the Canadian market in 2026, Phoenix’s poll also found two in five Canadians would be interested in trying them – TORONTO–(BUSINESS WIRE)–Today, Phoenix, Canada’s leading digital health clinic for men, released new poll data with insights from over 1,500 Canadians on sentiments around … [Read more…]

Jupiter Endovascular Announces Positive Results From SPIRARE I First-in-human Study Presented at TCT 2025

Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX) Technology Demonstrates Excellent Safety, Performance and Cardiac Recovery MENLO PARK, Calif.–(BUSINESS WIRE)–#TFX–Jupiter Endovascular, Inc., a medical technology company developing a new class of endovascular interventions using its proprietary Transforming Fixation (TFX) technology, today announced positive results from the SPIRARE I first-in-human (FIH) study. Data was presented at … [Read more…]

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) … [Read more…]

SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint System to Treat Rheumatoid Arthritis

Four presentations highlight 12-month clinical outcomes, as well as MRI-assessed joint protection and patient perspectives supporting the SetPoint System as first-of-its-kind treatment for rheumatoid arthritis (RA) VALENCIA, Calif.–(BUSINESS WIRE)–SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced it will share four presentations highlighting new data about the … [Read more…]